RIGImmune Announces New Funding to Advance Development of RNA Virus Treatments
07 déc. 2022 08h00 HE
|
RIGImmune
Program-Related Investment and Grant from the Bill & Melinda Gates Foundation to advance RIGImmune’s RNA therapeutics platform for influenza and pan-viral respiratory therapies Company also...
The Wellness Coalition is Hosting Free Flu and COVID-19 Vaccine Clinics in December for a Safer Holiday Season
01 déc. 2022 13h00 HE
|
The Wellness Coalition
MONTGOMERY, Ala., Dec. 01, 2022 (GLOBE NEWSWIRE) -- The Wellness Coalition is hosting community COVID-19 and flu vaccine clinics in Montgomery, Tuskegee, and Pike Road during the month of December....
Dyadic to Report Third Quarter 2022 Financial Results on Thursday, November 10, 2022
27 oct. 2022 16h30 HE
|
Dyadic International, Inc.
JUPITER, Fla., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building...
Dyadic Receives Regulatory Approval to Initiate Phase 1 Clinical Trial to Demonstrate Clinical Safety and Efficacy in Humans for DYAI-100 COVID-19 Recombinant Protein RBD Booster Vaccine Candidate
27 oct. 2022 09h04 HE
|
Dyadic International, Inc.
JUPITER, Fla., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building...
Vir Biotechnology Announces First Patient Dosed in Groundbreaking Phase 2 Trial of VIR-2482 for Antibody Prophylaxis of Influenza A
18 oct. 2022 08h00 HE
|
Vir Biotechnology, Inc.
– First clinical trial evaluating the role of a monoclonal antibody in preventing seasonal flu – – Announcement follows recent U.S. government award from the Biomedical Advanced Research and...
Dyadic to Present Disruptive C1 Technology at World Vaccine Congress Europe Announcing Expansion of Influenza Pipeline with Enhanced Efficacy Potential
04 oct. 2022 08h45 HE
|
Dyadic International, Inc.
JUPITER, Fla., Oct. 04, 2022 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial...
Vir Biotechnology Awarded U.S. Government Contract to Support Pandemic Preparedness for Influenza and Other Infectious Disease Threats
04 oct. 2022 08h00 HE
|
Vir Biotechnology, Inc.
– First award from the agency’s solicitation for contracts for Pre-Exposure Prophylaxis for Influenza – – Initial investment of approximately $55 million from Biomedical Advanced Research and...
Global Respiratory Disease Testing Market Expected to Garner a Revenue of $20.1 Billion by 2027, despite COVID-19 Crisis | | Declared by Research Dive
14 sept. 2022 09h02 HE
|
Research Dive
New York, USA, Sept. 14, 2022 (GLOBE NEWSWIRE) -- According to the report published by Research Dive, the global respiratory disease testing market is anticipated to generate a revenue of $20.1...
Dyadic Updates Market on Recent Scientific Achievements
13 sept. 2022 08h00 HE
|
Dyadic International, Inc.
JUPITER, Fla., Sept. 13, 2022 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial...
Blue Water Vaccines to Present at The Universal Influenza Vaccines 2022 Conference in Oxford, United Kingdom
24 août 2022 14h00 HE
|
Blue Water Vaccines Inc.
CINCINNATI, Aug. 24, 2022 (GLOBE NEWSWIRE) -- Blue Water Vaccines Inc. (“BWV” or “Blue Water Vaccines” or “the Company”) a biopharmaceutical company developing transformational vaccines to address...